Skip to main content

Rheumatoid Arthritis

      #Poorer responses to #Rx in
      #Females vs #males

      Sex hormone and pathway differences
      explained
      👇
      Biological differe
      1 month ago
      #Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA.
      RA patients vaccinated with PCV13
      VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropos
      Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA
      Dumoulin et al. 4 year results of TREAT EARLIER trial of 1 year MTX in CSA. In high risk ACPA- group, reduced risk of RA development, 8.6% vs 29%, HR 0.27. No difference at 4 years in ACPA+ or low risk ACPA- @RheumNow #ACR24 Abstr#2672 #ACRbest https://t.co/S2yJm196UV https://t.co/bJ9JySteUs
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA a
      1 month ago
      In the AMPLIFIED study (phase 3, single-blind RCT) ABA not superior to ADA in patients with dual seropositive early RA and HLA Class II #ACR24 @RheumNow ABST#2671 https://t.co/VSorAiJUIe
      The ORAL surveillance trial raised safety concerns that the janus kinase inhibitor (JAKi) tofacitinib was associated with an increased incidence of cancer and major adverse cardiovascular events…
      Day 3 Recap: ACR 2024
      Is Pregnancy Truly the Solution for RA?

      Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has
      1 month ago
      Is Pregnancy Truly the Solution for RA? Pregnancy is perhaps the oldest treatment in rheumatoid arthritis (RA) and has been associated with a natural improvement in disease control in 50-75% of patients. Others, however, are not as successful with unchanged disease activity or… https://t.co/MesVIUl0fC https://t.co/760i5znmeu
      ×